Impact of the oral adsorbent AST-120 on oxidative stress and uremic toxins in high-risk chronic kidney disease patients

Int J Cardiol. 2014 Dec 15;177(2):705-7. doi: 10.1016/j.ijcard.2014.09.196. Epub 2014 Oct 5.

Authors

Shigeru Toyoda¹, Migaku Kikuchi¹, Takaaki Komatsu², Yuichi Hori², Shiro Nakahara², Sayuki Kobayashi², Yoshihiko Sakai², Teruo Inoue¹, Isao Taguchi³

Affiliations

¹ Department of Cardiovascular Medicine, Dokkyo Medical University, Tochigi, Japan.
² Department of Cardiology, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan.
³ Department of Cardiology, Dokkyo Medical University Koshigaya Hospital, Saitama, Japan. Electronic address: taguchi@dokkyomed.ac.jp.

PMID: 25449490
DOI: 10.1016/j.ijcard.2014.09.196

No abstract available

Keywords: AST-120; Chronic kidney disease; High risk patients; Oxidative stress; Uremic toxins.

Publication types

Letter
Randomized Controlled Trial

MeSH terms

Administration, Oral
Adsorption / drug effects
Adsorption / physiology*
Aged
Aged, 80 and over
Carbon / administration & dosage*
Female
Humans
Male
Middle Aged
Oxidative Stress / drug effects
Oxidative Stress / physiology*
Oxides / administration & dosage*
Renal Insufficiency, Chronic / diagnosis
Renal Insufficiency, Chronic / drug therapy
Renal Insufficiency, Chronic / urine*
Risk Factors
Toxins, Biological / urine
Uremia / diagnosis
Uremia / drug therapy
Uremia / urine*

Substances

Oxides
Toxins, Biological
uremia middle molecule toxins
Carbon
AST 120